Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges

Randomized clinical trials (RCTs) are among the most rigorous ways to determine the causal relationship between an intervention and important clinical outcome. Their use in veterinary medicine has become increasingly common, and as is often the case, with progress comes new challenges. Randomized clinical trials yield important answers, but results from these studies can be unhelpful or even misleading unless the study design and reporting are carried out with care. Herein, we offer some perspective on several emerging challenges associated with RCTs, including use of composite endpoints, the reporting of different forms of risk, analysis in the presence of missing data, and issues of reporting and safety assessment. These topics are explored in the context of previously reported veterinary internal medicine studies as well as through illustrative examples with hypothetical data sets. Moreover, many insights germane to RCTs in veterinary internal medicine can be drawn from the wealth of experience with RCTs in the human medical field. A better understanding of the issues presented here can help improve the design, interpretation, and reporting of veterinary RCTs.

[1]  W. Sischo,et al.  A Randomized Clinical Trial Evaluating the Effects of Oligosaccharides on Transfer of Passive Immunity in Neonatal Dairy Calves , 2016, Journal of veterinary internal medicine.

[2]  Ravi Varadhan,et al.  Evaluating Health Outcomes in the Presence of Competing Risks: A Review of Statistical Methods and Clinical Applications , 2010, Medical care.

[3]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[4]  Kathryn C. Loeser,et al.  Intention-to-treat and transparency of related practices in randomized, controlled trials of anti-infectives , 2016, BMC Medical Research Methodology.

[5]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[6]  G. Guyatt,et al.  Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. , 2007, Journal of clinical epidemiology.

[7]  Joel Huber,et al.  Weighting composite endpoints in clinical trials: essential evidence for the heart team. , 2012, The Annals of thoracic surgery.

[8]  J. Valcour,et al.  Quality of reporting of clinical trials of dogs and cats and associations with treatment effects. , 2010, Journal of veterinary internal medicine.

[9]  Sylvie Chabaud,et al.  Experimental designs for small randomised clinical trials: an algorithm for choice , 2013, Orphanet Journal of Rare Diseases.

[10]  J. Heller Epidemiological and statistical considerations for interpreting and communicating oncology clinical trials. , 2015, Veterinary journal.

[11]  J. Sargeant,et al.  The REFLECT Statement: Reporting Guidelines for Randomized Controlled Trials in Livestock and Food Safety: Explanation and Elaboration † , 2010, Journal of food protection.

[12]  Jeroen J. Bax,et al.  Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency , 2016, European journal of heart failure.

[13]  Deficiencies of effectiveness of intervention studies in veterinary medicine: a cross-sectional survey of ten leading veterinary and medical journals , 2016 .

[14]  D. Kent,et al.  Reporting clinical trial results to inform providers, payers, and consumers. , 2005, Health affairs.

[15]  J. Bonagura,et al.  Acute Effects of Ivabradine on Dynamic Obstruction of the Left Ventricular Outflow Tract in Cats with Preclinical Hypertrophic Cardiomyopathy , 2014, Journal of veterinary internal medicine.

[16]  S. Pocock,et al.  Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials. , 2015, Journal of the American College of Cardiology.

[17]  D. Kent,et al.  Competing risk and heterogeneity of treatment effect in clinical trials , 2008, Trials.

[18]  P. Fox,et al.  Long‐term Outcome of Irish Wolfhound Dogs with Preclinical Cardiomyopathy, Atrial Fibrillation, or Both Treated with Pimobendan, Benazepril Hydrochloride, or Methyldigoxin Monotherapy , 2016, Journal of veterinary internal medicine.

[19]  N. Di Girolamo,et al.  Deficiencies of effectiveness of intervention studies in veterinary medicine: a cross-sectional survey of ten leading veterinary and medical journals , 2016, PeerJ.

[20]  Nick Freemantle,et al.  Composite outcomes in randomized trials: greater precision but with greater uncertainty? , 2003, JAMA.

[21]  David Moher,et al.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. , 2010, Obstetrics and gynecology.

[22]  Anna C. Balazs,et al.  Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. , 1980, The New England journal of medicine.

[23]  M. Giuffrida Defining the primary research question in veterinary clinical studies. , 2016, Journal of the American Veterinary Medical Association.

[24]  Ê. Ferreira,et al.  Quantitation of the Regional Lymph Node Metastatic Burden and Prognosis in Malignant Mammary Tumors of Dogs , 2015, Journal of veterinary internal medicine.

[25]  Scoring System for Multiple Organ Dysfunction in Adult Horses with Acute Surgical Gastrointestinal Disease , 2016, Journal of veterinary internal medicine.

[26]  S. Shapiro,et al.  The intention-to-treat approach in randomized controlled trials: Are authors saying what they do and doing what they say? , 2007, Clinical trials.

[27]  M. Giuffrida Type II error and statistical power in reports of small animal clinical trials. , 2014, Journal of the American Veterinary Medical Association.

[28]  I R Dohoo,et al.  The REFLECT statement: reporting guidelines for randomized controlled trials in livestock and food safety: explanation and elaboration. , 2010, Journal of food protection.

[29]  Mohammad Mahdi Jalali,et al.  Effect of a Probiotic on Prevention of Diarrhea and Clostridium difficile and Clostridium perfringens Shedding in Foals , 2015, Journal of veterinary internal medicine.

[30]  N. Cohen,et al.  Gallium Maltolate as an Alternative to Macrolides for Treatment of Presumed Rhodococcus equi Pneumonia in Foals , 2015, Journal of veterinary internal medicine.

[31]  David M Kent,et al.  Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal , 2010, Trials.

[32]  D. M. Hassel,et al.  Clinical features and prognostic variables in 109 horses with esophageal obstruction (1992-2009). , 2010, Journal of veterinary internal medicine.

[33]  R. Kruse,et al.  Intention-to-treat analysis: who is in? Who is out? , 2002, The Journal of family practice.

[34]  A. Detsky,et al.  Composite end points in randomized trials: there is no free lunch. , 2010, JAMA.

[35]  David L. DeMets,et al.  Data Monitoring Committees in Clinical Trials , 2002 .

[36]  J. McMurray,et al.  Statistical Controversies in Reporting of Clinical Trials: Part 2 of a 4-Part Series on Statistics for Clinical Trials. , 2015, Journal of the American College of Cardiology.

[37]  J. Wofford,et al.  A Prospective, Randomized, Masked, Placebo‐Controlled Multisite Clinical Study of Grapiprant, an EP4 Prostaglandin Receptor Antagonist (PRA), in Dogs with Osteoarthritis , 2016, Journal of veterinary internal medicine.

[38]  J. Ball,et al.  Statistics review 12: Survival analysis , 2004, Critical care.

[39]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[40]  J. Häggström,et al.  Survival characteristics and prognostic variables of dogs with preclinical chronic degenerative mitral valve disease attributable to myxomatous degeneration. , 2012, Journal of veterinary internal medicine.

[41]  J. Wofford,et al.  A Prospective, Randomized, Masked, Placebo‐Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite , 2016, Journal of veterinary internal medicine.

[42]  Gordon H Guyatt,et al.  Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials , 2007, BMJ : British Medical Journal.

[43]  J. PérezMartín,et al.  [International Committee of Medical Journal Editors]. , 2008, Revista alergia Mexico.

[44]  M. Chigerwe,et al.  A Randomized Clinical Trial Evaluating Metabolism of Colostral and Plasma Derived Immunoglobulin G in Jersey Bull Calves , 2015, Journal of veterinary internal medicine.

[45]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, Journal of clinical epidemiology.

[46]  Shiliang Huang,et al.  NF-κB-Dependent Upregulation of NCX1 Induced by Angiotensin II Contributes to Calcium Influx in Rat Aortic Smooth Muscle Cells. , 2016, The Canadian journal of cardiology.

[47]  K. Muñana,et al.  A Placebo‐Controlled, Prospective, Randomized Clinical Trial of Polyethylene Glycol and Methylprednisolone Sodium Succinate in Dogs with Intervertebral Disk Herniation , 2015, Journal of veterinary internal medicine.

[48]  J. Elliott,et al.  The combined prognostic potential of serum high-sensitivity cardiac troponin I and N-terminal pro-B-type natriuretic peptide concentrations in dogs with degenerative mitral valve disease. , 2012, Journal of veterinary internal medicine.

[49]  Ewout W Steyerberg,et al.  Competing risks and the clinical community: irrelevance or ignorance? , 2011, Statistics in medicine.

[50]  C. Rodriguez,et al.  Randomized Phase III Trial of Piroxicam in Combination with Mitoxantrone or Carboplatin for First‐Line Treatment of Urogenital Tract Transitional Cell Carcinoma in Dogs , 2015, Journal of veterinary internal medicine.

[51]  Patrick Royston,et al.  Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit , 2011, Trials.

[52]  David M Kent,et al.  Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. , 2007, JAMA.

[53]  John Hoey,et al.  Clinical trial registration: a statement from the International Committee of Medical Journal Editors. , 2004, JAMA.

[54]  E. Skjerve,et al.  Effect of Ovariohysterectomy at the Time of Tumor Removal in Dogs with Mammary Carcinomas: A Randomized Controlled Trial , 2015, Journal of veterinary internal medicine.

[55]  K. Muñana,et al.  Effect of Cranberry Extract on the Frequency of Bacteriuria in Dogs with Acute Thoracolumbar Disk Herniation: A Randomized Controlled Clinical Trial , 2016, Journal of veterinary internal medicine.

[56]  Viv Bewick,et al.  Statistics review 11: Assessing risk , 2004, Critical care.

[57]  H. Weng,et al.  Secondary prevention of cardiogenic arterial thromboembolism in the cat: The double-blind, randomized, positive-controlled feline arterial thromboembolism; clopidogrel vs. aspirin trial (FAT CAT). , 2015, Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology.

[58]  J. Lau,et al.  The impact of high-risk patients on the results of clinical trials. , 1997, Journal of clinical epidemiology.

[59]  J. Elliott,et al.  The Effect of Moderate Dietary Protein and Phosphate Restriction on Calcium‐Phosphate Homeostasis in Healthy Older Cats , 2016, Journal of veterinary internal medicine.

[60]  J. Elliott,et al.  Comparison of Efficacy of Long‐term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease , 2015, Journal of veterinary internal medicine.

[61]  Lisa M. Schwartz,et al.  Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review , 2010, BMJ : British Medical Journal.

[62]  J M Lachin,et al.  Statistical considerations in the intent-to-treat principle. , 2000, Controlled clinical trials.

[63]  K. Anstrom,et al.  Composite End Points in Acute Heart Failure Research: Data Simulations Illustrate the Limitations. , 2016, The Canadian journal of cardiology.

[64]  Kurt Lohman,et al.  Interpreting measures of treatment effect in cancer clinical trials. , 2002, The oncologist.

[65]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[66]  M. L. O’Sullivan,et al.  Efficacy of Pimobendan in the Prevention of Congestive Heart Failure or Sudden Death in Doberman Pinschers with Preclinical Dilated Cardiomyopathy (The PROTECT Study) , 2012, Journal of veterinary internal medicine.

[67]  M. L. O’Sullivan,et al.  Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial , 2016, Journal of veterinary internal medicine.

[68]  L. Duchateau,et al.  Clinical, Pathologic, and Immunohistochemical Prognostic Factors in Dogs with Thyroid Carcinoma , 2014, Journal of veterinary internal medicine.

[69]  U. Dafni,et al.  Informed Choice of Composite End Points in Cardiovascular Trials , 2014, Circulation. Cardiovascular quality and outcomes.

[70]  B. Meij,et al.  The Prognostic Value of Perioperative Profiles of ACTH and Cortisol for Recurrence after Transsphenoidal Hypophysectomy in Dogs with Corticotroph Adenomas , 2015, Journal of veterinary internal medicine.

[71]  J. Bland,et al.  Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. , 2010, Journal of veterinary internal medicine.

[72]  S. Buczinski,et al.  Preoperative and Postoperative L‐Lactatemia Assessment for the Prognosis of Right Abomasal Disorders in Dairy Cattle , 2014, Journal of veterinary internal medicine.

[73]  D. Werling,et al.  A Prospective, Randomized, Blinded, Placebo‐Controlled Pilot Study on the Effect of Enterococcus faecium on Clinical Activity and Intestinal Gene Expression in Canine Food‐Responsive Chronic Enteropathy , 2015, Journal of veterinary internal medicine.

[74]  John Hoey,et al.  Clinical trial registration: a statement from the International Committee of Medical Journal Editors. , 2005, Circulation.

[75]  M. Faires,et al.  Reporting of methodological features in observational studies of pre-harvest food safety. , 2011, Preventive veterinary medicine.

[76]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[77]  R. Brian Haynes,et al.  Forming research questions☆ , 2006, Journal of Clinical Epidemiology.

[78]  E. Cobo,et al.  Discordance between reported intention-to-treat and per protocol analyses. , 2007, Journal of clinical epidemiology.

[79]  J. Häggström,et al.  Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. , 2008, Journal of veterinary internal medicine.

[80]  William White,et al.  A Proposal , 2008, Moon, Sun, and Witches.

[81]  J. Elliott,et al.  Randomized Placebo‐Controlled Clinical Trial of a Chewable Formulation of Amlodipine for the Treatment of Hypertension in Client‐Owned Cats , 2015, Journal of veterinary internal medicine.